AR116632A1 - Polipéptidos análogos de la amilina humana y sus métodos de uso - Google Patents

Polipéptidos análogos de la amilina humana y sus métodos de uso

Info

Publication number
AR116632A1
AR116632A1 ARP190102894A ARP190102894A AR116632A1 AR 116632 A1 AR116632 A1 AR 116632A1 AR P190102894 A ARP190102894 A AR P190102894A AR P190102894 A ARP190102894 A AR P190102894A AR 116632 A1 AR116632 A1 AR 116632A1
Authority
AR
Argentina
Prior art keywords
methods
analog polypeptides
amylin
disclosed
human
Prior art date
Application number
ARP190102894A
Other languages
English (en)
Inventor
James M Way
Ved P Srivastava
William Blackwell
Original Assignee
Intarcia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intarcia Therapeutics Inc filed Critical Intarcia Therapeutics Inc
Publication of AR116632A1 publication Critical patent/AR116632A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Polipéptidos aislados que son análogos de la amilina humana. Los polipéptidos análogos de amilina divulgados tienen propiedades fisicoquímicas beneficiosas relacionadas con la amilina endógena, tales como vidas medias (t₁/₂) de eliminación más prolongadas y una solubilidad y estabilidad térmica mejoradas. Esta también se relaciona con métodos para usar los polipéptidos análogos de amilina divulgados en una variedad de indicaciones terapéuticas, así como métodos para producir los mismos. Los polipéptidos análogos de amilina divulgados son de particular utilidad en los métodos de tratamiento de enfermedades o trastornos metabólicos, tal como las diabetes de los tipos 1 y 2, y también proveen pérdida de peso.
ARP190102894A 2018-10-11 2019-10-10 Polipéptidos análogos de la amilina humana y sus métodos de uso AR116632A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862744236P 2018-10-11 2018-10-11

Publications (1)

Publication Number Publication Date
AR116632A1 true AR116632A1 (es) 2021-05-26

Family

ID=68393080

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102894A AR116632A1 (es) 2018-10-11 2019-10-10 Polipéptidos análogos de la amilina humana y sus métodos de uso

Country Status (14)

Country Link
US (1) US20200115430A1 (es)
EP (1) EP3864031A1 (es)
JP (1) JP2022504596A (es)
KR (1) KR20210091705A (es)
CN (1) CN113195524A (es)
AR (1) AR116632A1 (es)
AU (1) AU2019357621A1 (es)
BR (1) BR112021006823A2 (es)
CA (1) CA3116023A1 (es)
IL (1) IL282079A (es)
MX (1) MX2021004185A (es)
SG (1) SG11202103586UA (es)
TW (1) TW202028228A (es)
WO (1) WO2020077129A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023522944A (ja) * 2020-04-20 2023-06-01 アイツーオー・セラピューティクス・インコーポレイテッド １型糖尿病患者に優れた血糖制御をもたらすためのヒトアミリンアナログポリペプチドの使用
EP4021929B1 (en) * 2020-09-24 2023-04-26 Gubra ApS Ham15-52 analogues with improved amylin receptor (hamy3r) potency
CN113880935B (zh) * 2021-10-25 2022-08-26 浙江肽昇生物医药有限公司 一种索马鲁肽全保护肽树脂的制备方法、一种索马鲁肽制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
ATE284413T1 (de) 1993-08-09 2004-12-15 Sod Conseils Rech Applic Therapeutische peptid derivate
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
EP0877599B1 (en) 1996-02-02 2003-03-26 Alza Corporation Sustained delivery of leuprolide using an implantable system
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
ATE223208T1 (de) 1997-12-22 2002-09-15 Alza Corp Membranen zur steuerung des durchflusses in vorrichtungen mit kontrollierter wirkstoffabgabe
CA2316976C (en) 1997-12-29 2009-02-17 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
ZA986627B (en) 1997-12-30 1999-03-05 Alza Corp Beneficial agent delivery system with membrane plug and method for controlling delivery of beneficial agents
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
KR100511855B1 (ko) 1998-12-07 2005-09-02 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. Ｇｌｐ-1의 유사체
NZ512671A (en) 1998-12-31 2003-12-19 Alza Corp Osmotic delivery system having space efficient piston
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
EA003922B1 (ru) 1999-05-17 2003-10-30 Конджачем, Инк. Продолжительно действующие инсулинотропные пептиды
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
AU773354B2 (en) 1999-12-21 2004-05-20 Intarcia Therapeutics, Inc. Valve for osmotic devices
US6706689B2 (en) 2000-05-19 2004-03-16 Amylin Pharmaceuticals, Inc. Treatment of acute coronary syndrome with GLP-1
DK1294757T3 (da) 2000-06-16 2007-03-19 Lilly Co Eli Glucagonlignende peptid 1-analoger
US7199217B2 (en) 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1
WO2002098348A2 (en) 2001-06-01 2002-12-12 Eli Lilly And Company Glp-1 formulations with protracted time action
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
MXPA04001525A (es) 2001-08-23 2004-05-31 Lilly Co Eli Analogos de peptido -1 similar al glucagon.
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
MXPA05000224A (es) 2002-06-26 2005-06-03 Alza Corp Piston de volumen eficiente, minimamente deformable, para sistemas de suministro osmotico de farmacos.
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
CA2520610A1 (en) 2003-03-31 2004-10-21 Alza Corporation Osmotic pump with means for dissipating internal pressure
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
NZ548978A (en) 2004-02-11 2009-10-30 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
WO2007104789A2 (en) * 2006-03-15 2007-09-20 Novo Nordisk A/S Amylin derivatives
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
EP3421031A1 (en) 2006-08-09 2019-01-02 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
JP5703226B2 (ja) * 2008-10-21 2015-04-15 ノヴォ ノルディスク アー／エス アミリン誘導体
JP2014521594A (ja) * 2011-05-25 2014-08-28 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 長持続期間デュアルホルモンコンジュゲート

Also Published As

Publication number Publication date
KR20210091705A (ko) 2021-07-22
CA3116023A1 (en) 2020-04-16
US20200115430A1 (en) 2020-04-16
JP2022504596A (ja) 2022-01-13
AU2019357621A1 (en) 2021-05-27
EP3864031A1 (en) 2021-08-18
CN113195524A (zh) 2021-07-30
IL282079A (en) 2021-05-31
MX2021004185A (es) 2021-09-08
SG11202103586UA (en) 2021-05-28
BR112021006823A2 (pt) 2021-07-27
WO2020077129A1 (en) 2020-04-16
TW202028228A (zh) 2020-08-01

Similar Documents

Publication Publication Date Title
AR116632A1 (es) Polipéptidos análogos de la amilina humana y sus métodos de uso
CL2011002430A1 (es) Variante de peptido natriuretico de tipo c (cnp); composicion farmaceutica que la comprende; metodo de produccion, celula huesped y uso de dicha variante.
CO2017000614A2 (es) Polipéptidos gdf15 modificados y composiciones de los mismos
PE20181139A1 (es) Composiciones y metodos para inhibir la expresion genica de lpa
ECSP14030742A (es) Proteínas del factor 21 de crecimiento del fibroblasto
CO2020015153A2 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
CR8118A (es) Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
EA201792602A1 (ru) Стволовые клетки плацентарного происхождения и их применение для восстановления регенеративного механизма, коррекции протеомных дефектов и продления жизни стареющих индивидуумов
CO6541602A2 (es) Composiciones orales que contienen extractos de zizyphus joazeiro y método relacionados
CO6280409A2 (es) Anticuerpos antimesotelina y usos de los mismos
AR102301A1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
CU20120116A7 (es) Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5
UY32060A (es) Anticuerpos anti-il-13 obtenidos mediante ingeniería, composiciones , métodos y usos
UY31689A1 (es) Derivados de platino-carbeno n-heterocíclico, su preparación y su aplicación en terapéutica
MX2017002469A (es) Composiciones de matrices extracelulares.
BR112022019020A2 (pt) Proteínas de fusão de il12 mascaradas e métodos de uso das mesmas
CL2021000938A1 (es) Composiciones estables de semaglutida y usos de las mismas
UY38200A (es) Conjugados de tirosina-tirosina de péptido cíclico acoplado a péptido de fusión de glp-1 y sus usos
CO2023013465A2 (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
CL2020000019A1 (es) Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso.
CL2020002641A1 (es) Composición para modular genes responsables de las funciones generales de la piel, que comprende un extracto vegetal de cichorium intybus y ceramidas de pasionaria (divisional de la solicitud 03354-2018)
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.
BR112021017853A2 (pt) Vetores de dna não virais e usos dos mesmos para expressar terapêuticas de fviii
BR112017006450A2 (pt) vetor adenoviral codificando atonal homólogo-1 de humano (hath1)
AR124395A1 (es) Agonistas del receptor del polipéptido tipo glucagón 1 (glp-1) de acción prolongada y métodos de uso de los mismos